Business Development

Strategic partnerships represent an important aspect of Intelliject's plan. It is critical to match excellent science & technology with world-class commercial expertise.

In the near term, Intelliject is evaluating commercial partners whose product portfolio would benefit from the addition of the novel, patent-protected EpiCard™. The EpiCard™ will allow the right commercial partner to offer a tremendous value proposition to all of its key partners & customers: Patients, Prescribers, Pharmacists, Distributors and Payers. Together, the collaboration will yield therapies with improved patient efficacy, compliance, and outcomes.

Beyond EpiCard™, Intelliject will seek commercial partners interested in its proprietary platforms to add significant value to existing market-approved products and also for the development of new therapeutic products. Therapeutic and economic goals will be realized with patient-centric approaches that leverage Intelliject's technology combined with its partners commercial expertise.

Kris Ford
Vice President, Business Development
804.545.6375
kris.ford@intelliject.com